China High Quality Lidocaine Hydrochloride Suppliers – 99% Apixaban CAS 503612-47-3 – Baoran

Short Description:

Product Detail

Product Tags

Feedback (2)

Our personnel are generally within the spirit of "continuous improvement and excellence", and using the excellent top quality goods, favorable rate and superior after-sales expert services, we try to win every customer's believe in for Boron Oxide, Procaine, 112-34-5, We hope to establish more business relationships with customers all over the world.

China High Quality Lidocaine Hydrochloride Suppliers – 99% Apixaban CAS 503612-47-3 – Baoran Detail:

Specification

ITEM	STANDARD
Appearance	White to off-white solid
Purity	≥ 99%

Application

On April 26, 2007, Bristol-Myers Squibb and Pfizer announced a joint development of the new oral anticoagulant apixaban owned by Bristol-Myers Squibb as an upgraded alternative to warfarin.
In May 2011, apixaban was the first to be approved for the prevention of venous thrombosis in adult patients undergoing elective hip or knee replacement surgery in 27 EU countries, Iceland and Norway.
On November 20, 2012, the European Commission approved ELIQUIS (apixaban) for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) with one or more risk factors.
The Canadian Food and Drug Administration, Japan, and the U.S. Food and Drug Administration subsequently approved ELIQUIS (apixaban) for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) with one or more risk factors.
On April 12, 2013, ELIQUIS (Apixaban), was officially announced on the market in China. Apixaban is a novel oral factor Xa inhibitor for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery. Its launch provides a safe and effective new option for anticoagulation after orthopaedic surgery in clinical practice, and brings good news to Chinese patients undergoing elective hip/knee replacement.
Clinical studies have confirmed that compared with 40 mg subcutaneous injection of enoxaparin once a day, 2.5 mg of ELIQUIS (Apixaban) orally twice a day is more effective in preventing venous thromboembolic events after hip or knee replacement surgery , and does not increase the risk of bleeding.

Packing & Storage

100g/500g/1kg/25kg or as request;
Stored at room temperature and airtight.

Product detail pictures:

Related Product Guide:

owing to fantastic assistance, a variety of high quality goods, aggressive rates and efficient delivery, we love a very good popularity among our customers. We are an energetic firm with wide market for China High Quality Lidocaine Hydrochloride Suppliers – 99% Apixaban CAS 503612-47-3 – Baoran, The product will supply to all over the world, such as: Norwegian, Argentina, Nicaragua, Hard work to keep making progress, innovation in the industry, make every effort to first-class enterprise. We try our best to build the scientific management model, to learn abundant experienced knowledge, to develop advanced production equipment and production process , to create the first-call quality goods, reasonable price , high quality of service , quick delivery , to present you create new value .

17639-93-9